Pityriasis Lichenoides Devang G
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Lymphomatoid Papulosis and Recurrent Transitional Cell Carcinoma
Volume 20 Number 4 April 2014 Letter Lymphomatoid papulosis and recurrent transitional cell carcinoma of the bladder: a paraneoplastic association WMS Leong1, CWD Aw1, KB Tan2 Dermatology Online Journal 20 (4): 17 1Division of Dermatology, National University Hospital, Singapore 2Department of Pathology, National University Hospital, Singapore Correspondence: Wai Mun Sean Leong, M.B.B.S. University Medicine Cluster National University Hospital 5 Lower Kent Ridge Road Singapore 119074 Phone: 67795555 Email: [email protected] Abstract Lymphomatoid papulosis is a rare, papulonodular skin eruption with histologic features of a CD30+ T cell lymphoma. We present a 79-year-old man with lymphomatoid papulosis and transitional cell carcinoma of the bladder. Introduction Lymphomatoid papulosis (LyP) is a rare, recurrent, self-healing papulonodular skin eruption with histologic features of a CD30+ malignant T cell lymphoma [1]. It belongs to a group of cutaneous CD30+ lymphoproliferative disorders, which includes cutaneous T cell lymphoma [2]. Patients with LyP are at risk of developing a second cutaneous or nodal lymphoma [3,4]. However, an association with transitional cell carcinoma (TCC) of the bladder has not been reported in the literature. This case illustrates a possible association between these two conditions. Case synopsis A 79-year-old man complained of a slightly itchy rash on the arms, neck, and shoulders for one year. Betamethasone- gentamicin cream previously afforded partial improvement. Approximately 9 months prior to presentation at the dermatology clinic, he was diagnosed to have TCC of the bladder (T1G3) and had undergone a trans-urethral resection of bladder cancer (TURBT) in December 2006 and January 2007. -
Comorbidities in Mycosis Fungoides and Racial Differences In
medicines Article Comorbidities in Mycosis Fungoides and Racial Differences in Co-Existent Lymphomatoid Papulosis: A Cross-Sectional Study of 580 Patients in an Urban Tertiary Care Center Subuhi Kaul 1,*, Micah Belzberg 2, John-Douglas Matthew Hughes 3, Varun Mahadevan 2 , Raveena Khanna 2, Pegah R. Bakhshi 2, Michael S. Hong 2, Kyle A. Williams 2, 2 2, 2, Annie L. Grossberg , Shawn G. Kwatra y and Ronald J. Sweren y 1 Department of Medicine, John H. Stroger Hospital of Cook County, Chicago, IL 60612, USA 2 Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA; [email protected] (M.B.); [email protected] (V.M.); [email protected] (R.K.); [email protected] (P.R.B.); [email protected] (M.S.H.); [email protected] (K.A.W.); [email protected] (A.L.G.); [email protected] (S.G.K.); [email protected] (R.J.S.) 3 Section of Dermatology, University of Calgary, Alberta, AB T2N 1N4, Canada; [email protected] * Correspondence: [email protected]; Tel.: +1-312-864-7000 Considered co-senior authors. y Received: 26 October 2019; Accepted: 24 December 2019; Published: 26 December 2019 Abstract: Background: Mycosis fungoides (MF) is a cutaneous T-cell lymphoma. Previous reports have suggested MF is associated with inflammatory conditions such as psoriasis, increased cardiovascular risk factors as well as secondary neoplasms. Methods: A cross-sectional study of MF patients seen from 2013 to 2019 was performed. Comorbidities were selected based on the 2015 Medicare report highlighting the most common chronic medical illnesses in the United States. -
Primary Cutaneous Anaplastic Large Cell Lymphoma / Lymphomatoid
Primary Cutaneous CD30-Positive T-cell Lymphoproliferative Disorders Definition A spectrum of related conditions originating from transformed or activated CD30-positive T-lymphocytes May coexist in individual patients Clonally related Overlapping clinical and/or histological features Clinical, histologic, and phenotypic characteristics required for diagnosis Types 1. Primary cutaneous anaplastic large cell lymphoma (C-ALCL) 2. Lymphomatoid papulosis 3. Borderline lesions C-ALCL: Definition T-cell lymphoma, presenting in the skin and consisting of anaplastic lymphoid cells, the majority of which are CD30- positive Distinction from: (a) systemic ALCL with cutaneous involvement, and (b) secondary high-grade lymphomas with CD30 expression In nearly all patients disease is limited to the skin at the time of diagnosis Assessed by meticulous staging Patients should not have other subtypes of lymphoma C-ALCL: Synonyms Lukes-Collins: Not listed (T-immunoblastic) Kiel: Anaplastic large cell Working Formulation: Various categories (diffuse large cell; immunoblastic) REAL: Primary cutaneous anaplastic large cell (CD30+) lymphoma Related terms: Regressing atypical histiocytosis; Ki-1 lymphoma C-ALCL: Epidemiology 25% of the T-cell lymphomas arising primarily in the skin. Predominantly in adults/elderly and rare in children. The male to female ratio is 1.5-2.0:1. C-ALCL: Sites of Involvement The disease is nearly always limited to the skin at the time of diagnosis Extracutaneous dissemination may occur Mainly regional lymph nodes Involvement of other organs is rare C-ALCL: Clinical Features Most present solitary or localized skin lesions which may be tumors, nodules or (more rarely) papules Multicentric cutaneous disease occurs in 20% Lesions may show partial or complete spontaneous regression (similar to lymphomatoid papulosis) Cutaneous relapses are frequent Extracutaneous dissemination occurs in approximately 10% of the patients. -
18F-FDG Avidity in Lymphoma Readdressed: a Study of 766 Patients
Journal of Nuclear Medicine, published on December 15, 2009 as doi:10.2967/jnumed.109.067892 18F-FDG Avidity in Lymphoma Readdressed: A Study of 766 Patients Michal Weiler-Sagie1, Olga Bushelev2, Ron Epelbaum2,3, Eldad J. Dann2,4,5, Nissim Haim2,3, Irit Avivi2,5, Ayelet Ben-Barak6, Yehudit Ben-Arie2,7, Rachel Bar-Shalom1,2, and Ora Israel1,2 1Department of Nuclear Medicine, Rambam Health Care Campus, Haifa, Israel; 2Ruth and Bruce Rappaport Faculty of Medicine, Technion–Israel Institute of Technology, Haifa, Israel; 3Department of Oncology, Rambam Health Care Campus, Haifa, Israel; 4Blood Bank and Apheresis Unit, Rambam Health Care Campus, Haifa, Israel; 5Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel; 6Department of Pediatric Hematology-Oncology, Meyer Children’s Hospital, Rambam Health Care Campus, Haifa, Israel; and 7Department of Pathology, Rambam Health Care Campus, Haifa, Israel PET/CT with 18F-FDG is an important noninvasive diagnostic tool for management of patients with lymphoma, and its use may sur- Lymphoma is a heterogeneous group of diseases rep- pass current guideline recommendations. The aim of the present resenting the fifth most common malignancy in the United study is to enlarge the growing body of evidence concerning 18F- FDG avidity of lymphoma to provide a basis for future guidelines. States, with an estimated 74,340 new cases predicted for Methods: The reports from 18F-FDG PET/CT studies performed 2008 (1). Subtypes of lymphoma differ in molecular char- in a single center for staging of 1,093 patients with newly diag- acteristics and biologic behavior. Based on clinical charac- nosed Hodgkin disease and non-Hodgkin lymphoma between teristics, this entity is divided into aggressive and indolent 2001 and 2008 were reviewed for the presence of 18F-FDG avid- types (2,3). -
Landispiwowar.Kristin.Genetics of Select Lymphoproliferative
3/21/16 Objecves Gene+cs of Select • Define tumor suppressor gene and oncogene Lymphoproliferave Neoplasms: • Correlate genotypes Pathophysiology, Prognos+caon, and Therapy with prognosis in lymphoproliferave neoplasms Kris+n Landis-Piwowar PhD, MLS(ASCP)CM • Recognize the targets of lymphoproliferave Clinical Laboratory Hematology, 3/E, McKenzie • Williams neoplasm therapies 2 Leukemia Lymphoma WHO 2008: Mature B-Cell Neoplasms • Chronic lymphocy+c leukemia/small lymphocy+c • Mantle cell lymphoma lymphoma • Diffuse large B-cell lymphoma (DLBCL), NOS • Primarily BM and • Primarily lymph • B-cell prolymphocyc leukemia • T-cell/his+ocyte rich large B-cell lymphoma • Primary DLBCL of the CNS • Splenic marginal zone lymphoma • Primary cutaneous DLBCL, leg type blood involvement node / solid ssue • Hairy cell leukemia • EBV-posi+ve DLBCL of the elderly • Splenic lymphoma/leukemia, unclassifiable • DLBCL associated with chronic inflammaon • Splenic diffuse red pulp small B-cell lymphoma • Lymphomatoid granulomatosis • Hairy cell leukemia variant involvement • Primary medias+nal (thymic) large B-cell lymphoma • Myeloid or • Lymphoplasmacy+c lymphoma • Intravascular large B-cell lymphoma • Waldenström macroglobulinemia • ALK-posi+ve large B-cell lymphoma lymphoid origin • Lymphoid origin • Heavy chain diseases • α Heavy chain disease • Plasmablas+c lymphoma • γ Heavy chain disease • Large B-cell lymphoma arising in HHV8-associated • May secondarily • May secondarily • μ Heavy chain disease mul+centric Castleman disease • Plasma cell myeloma • Primary -
Successful Treatment of CD30+Lymphomatoid Papulosis
ooggeenneessii iinn ss && rrcc aa MM CC uu tt ff aa Journal ofJournal of oo gg ll ee ee aa aa nn nn nn nn ee ee rr rr ss ss uu uu ii ii Watabe et al., J Carcinog Mutagen 2014, 5:3 ss ss oo oo JJ JJ ISSN: 2157-2518 CarCarcinogenesiscinogenesis & Mutagenesis DOI: 10.4172/2157-2518.1000174 Case Report Open Access Successful Treatment of CD30+Lymphomatoid Papulosis using a 308-nm Excimer Light Akiko Watabe, Taku Fujimura*, Sadanori Furudate and Setsuya Aiba Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan *Corresponding author: Taku Fujimura, Department of Dermatology, Tohoku University Graduate School of Medicine, Seiryo-machi 1-1, Aoba-ku, Sendai, 980-8574, Japan, Tel:+81 (22) 717-7271; Fax: +81 (22) 717-7361; E-mail: [email protected] Received date: Mar 11, 2014, Accepted date: May 03, 2014, Published date: May 07, 2014 Copyright: © 2013 Watabe A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited Abstract We describe a 61-year-old Japanese patient with Lymphomatoid papulosis (LYP) successfully archived complete remission, using a 308-nm Excimer light. Interestingly, immunohistochemical staining revealed that CD30+ anaplastic tumor cells were surrounded by CD163+ macrophages and CCL18 producing cells, both of which were reported to correlate with the prognosis of CTCL. Our present study sheds light on the possible pathogenesis of LYP and the possibility of a 308-nm Excimer light phototherapy for LYP. -
Lymphomatoid Papulosis Development in Acute Lymphoblastic Leukemia
Case Report J Med Cases. 2021;12(8):306-309 Lymphomatoid Papulosis Development in Acute Lymphoblastic Leukemia Kazumi Ouraa, Tomonobu Satoa, d , Akihiro Iguchib, Naohisa Toriumic, Takeo Sarashinac Abstract LyP is a rare disease with an incidence of 1.2 - 1.9 per million [1] and accounts for 16.0-47.0% of pediatric cutaneous lym- Lymphomatoid papulosis (LyP) is a chronic, recurrent benign skin phoproliferative disorders [2]. It has been reported that LyP disease characterized by histological features of a CD 30-positive cu- often disappears spontaneously and has a benign course [3, taneous T-cell lymphoproliferative disorder. It is rare, with an annual, 4]. However, a relationship between LyP and certain hemato- worldwide incidence of 1.2 - 1.9 per million, and accounts for 16-47% logical malignancies has also been reported [5-7]. Herein, we of pediatric cutaneous lymphoproliferative disorders. It often occurs describe a case in which tumors appeared in the left scrotum on the extremities or the trunk and rarely affects the face or genitals. and under the left lip during maintenance therapy for pre- Its onset may be triggered by irradiation therapy, immunomodulating cursor B-cell acute lymphoblastic leukemia (BCP-ALL). We agents, infection or atopic dermatitis. It has a benign course but is as- needed to distinguish the tumor from extramedullary recur- sociated with certain hematological malignancies. Mycosis fungoides rence of ALL or de novo other cutaneous lymphoma; how- and primary cutaneous anaplastic large cell lymphoma are the most ever, the histological findings of a tumor biopsy resulted in a commonly associated hematological malignancies. -
Co-Occurrence of Lymphomatoid Papulosis and Mycosis Fungoides in a Young Female: a Case Report Natalie Steinhoff, DO,* Brian Wanner,** Matthew H
Co-Occurrence of Lymphomatoid Papulosis and Mycosis Fungoides in a Young Female: A Case Report Natalie Steinhoff, DO,* Brian Wanner,** Matthew H. Mahoney, MD*** *Dermatology Resident, PGY-3, Nova Southeastern University College of Osteopathic Medicine, Largo Medical Center, Largo, FL **Osteopathic Medical Student, 4th year, Des Moines University College of Osteopathic Medicine, Des Moines, IA ***Dermatologist and Clinical Faculty, Nova Southeastern University College of Osteopathic Medicine, Largo Medical Center, Largo, FL Disclosures: None Correspondence: Natalie Steinhoff, DO; NSUCOM/Largo Medical Center; 201 14th St. SW, Largo, FL 33770; [email protected] Abstract There have been reports of lymphomatoid papulosis (LyP) and mycosis fungoides (MF) presenting separately, simultaneously, and consecutively. LyP is a CD30+ lymphoproliferative disorder, and MF is the most common cutaneous T-cell lymphoma (CTCL). LyP most often presents with self-regressing, erythematous-to-brown papules or small nodules. Mycosis fungoides has a variety of clinical manifestations, but in early stages it commonly presents as an erythematous patch or plaque. Recognizing LyP is important due to its association with development of secondary malignancies, most commonly MF, Hodgkin’s disease, and anaplastic large-cell lymphoma (ALCL). We report a case of a 35-year-old woman with recurrent LyP lesions since childhood who went on to develop concurrent LyP and MF. We discuss the need to evaluate LyP patients for secondary lymphomas and provide a concise review of the literature focusing on clinical presentation, diagnosis, disease associations, and management. microabscesses (mycosis cells in the epidermis), Spontaneous self-regression of lesions is required Introduction 3 19 Lymphomatoid papulosis (LyP) is one of two and a band-like dermal infiltrate of lymphocytes. -
Pityriasis Rosea DANIEL L
CARING FOR COMMON SKIN CONDITIONS Pityriasis Rosea DANIEL L. STULBERG, M.D., Utah Valley Regional Medical Center, Provo, Utah JEFF WOLFREY, M.D., Good Samaritan Regional Medical Center, Phoenix, Arizona Pityriasis rosea is a common, acute exanthem of uncertain etiology. Viral and bacterial causes have been sought, but convincing answers have not yet been found. Pityriasis O A patient informa- rosea typically affects children and young adults. It is characterized by an initial herald tion handout on pityriasis rosea, written patch, followed by the development of a diffuse papulosquamous rash. The herald by the authors of this patch often is misdiagnosed as eczema. Pityriasis rosea is difficult to identify until the article, is provided on appearance of characteristic smaller secondary lesions that follow Langer’s lines (cleav- page 94. age lines). Several medications can cause a rash similar to pityriasis rosea, and several diseases, including secondary syphilis, are included in the differential diagnosis. One small controlled trial reported faster clearing of the exanthem with the use of ery- thromycin, but the mechanism of effect is unknown. Resolution of the rash may be has- tened by ultraviolet light therapy but not without the risk of hyperpigmentation. Top- ical or systemic steroids and antihistamines often are used to relieve itching. (Am Fam Physician 2004;69:87-92,94. Copyright© 2004 American Academy of Family Physicians.) This article is one in a ityriasis rosea is a common skin cytes, a decrease in T lymphocytes, and an ele- series coordinated by condition characterized by a her- vated sedimentation rate.6 Daniel L. Stulberg, M.D., director of der- ald patch and the later appear- Unfortunately, even though electron matology curriculum at ance of lesions arrayed along microscopy shows some viral changes and the Utah Valley Family Langer’s lines (cleavage lines). -
Approach to Pediatric Psoriasis”, a Podcast Made for Pedscases.Com at the University of Alberta
Welcome to “Approach to Pediatric Psoriasis”, a podcast made for PedsCases.com at the University of Alberta. I am Dr. Harry Liu, a dermatology resident at the University of British Columbia, and I am David Jung, a medical student at the University of British Columbia. This podcast will provide an organized approach to understand pediatric psoriasis, a common dermatological condition in pediatric population. We would like to thank Dr. Joseph Lam, a pediatric dermatologist practicing in Vancouver, BC, Canada, for developing this podcast with us! 1 After listening to this podcast, we expect the learner to be able to: 1. Describe the typical clinical presentations of psoriasis 2. Discuss the underlying pathophysiology of psoriasis 3. Identify different types of psoriasis and their unique characteristics 4. Recall epidemiological risk factors and comorbidities associated with psoriasis 5. List common treatment options for pediatric psoriasis 2 First, we’d like to present a case. It is your day at an urban pediatric clinic as a fourth- year elective student. Your first patient is Lucy, an 8-year-old girl brought in by her mother for the concern of a newly developed rash. On history, Lucy has had the rash on her knees for about 3 months. The rash has gradually increased in size and has become quite scaly. When Lucy scratches, her mother also notices some bleeding. The mother is quite concerned because the rash has made many kids at school avoid Lucy. Before the development of the rash, Lucy had an episode of culture proven group A Streptococcal (GAS) pharyngitis which resolved with oral antibiotics; she is otherwise very healthy. -
History of Psoriasis and Parapsoriasis
History of Psoriasis and Parapsoriasis By Karl Holubar Summary Parapsoriasis is «oï a disease entity. Jt is an auxiliary term introduced in J 902 to group several dermatoses w>itk a/aint similarity to psoriasis. Tlie liistorical development leading to tlie creation o/ t/ie term parapsoriasis is outlined and t/te Itistory o/psoriasis is 6rie/ly reviewed. Semantic and terminological considerations Obviously, para-psoriasis as a term has been created in analogy to psoriasis. We should remember similar neologisms in medical language, e. g. protein and para-protein; typhoid and para-typhoid, thyroid and para-thyroid, phimosis and para-phimosis, eventually, pemphigus and para-pemphigus (the latter in 1955 this term was to be employed instead of pemphigoid but was not accepted by the dermatological world). Literally, para is a Greek preposition, (with the genitive, dative and accusative), meaning: by the side of, next to something, alongside something. In medicine, para is used often as a prefix to another term, which designates a condition somewhat similar to the one under consideration. The same holds for psoriasis and parapsoria- sis. In detail, though, it is a bit more complicated. Parapsoriasis has more than one "/at/ier", three in fact: ideiurick /Iu.spitz f 1835—1886,), Paul Gerson Luna (A850—1929j and Louis Procç fI856—I928J. Auspitz, in 1881, had published a new system of skin diseases the seventh class of which was called epidermidoses, subdivided into liypcrlcfiratose.s, parakeratoses, kerato/y- ses, the characteristics of which were excessive keratinization, abnormal keratinization and insufficent keratinization. When Unna, in 1890®, pub- lished his two reports on what he called parakeratosis variegata, he referred to Auspitz' system and term when coining his own. -
Errata to the 7/1/2016 Prioritized List
Errata to the 7/1/2016 Prioritized List 1) On 6/29/2017, the following corrections were made: a. Website addresses were corrected for the new Oregon Health Authority Web site in all guideline notes referencing a Coverage Guidance. In addition, a web address in the Multisector Interventions section on Tobacco Use was updated. b. M67.0 (Short Achilles tendon (acquired)) was moved to line 297 NEUROLOGICAL DYSFUNCTION IN POSTURE AND MOVEMENT CAUSED BY CHRONIC CONDITIONS from line 382 DYSFUNCTION RESULTING IN LOSS OF ABILITY TO MAXIMIZE LEVEL OF INDEPENDENCE IN SELF- DIRECTED CARE CAUSED BY CHRONIC CONDITIONS THAT CAUSE NEUROLOGICAL DYSFUNCTION c. Psoriasis corrections: i. Add psoriasis, parapsoriasis and similar ICD-10 codes to line 544 MILD PSORIASIS; DERMATOPHYTOSIS: SCALP, HAND, BODY, DEEP-SEATED 1. L40.0 Psoriasis vulgaris 2. L40.1 Generalized pustular psoriasis 3. L40.2 Acrodermatitis continua 4. L40.3 Pustulosis palmaris et plantaris 5. L40.4 Guttate psoriasis 6. L40.8 Other psoriasis 7. L40.9 Psoriasis, unspecified 8. L41.0 Pityriasis lichenoides et varioliformis acuta ii. Add psoriatic arthropathy ICD-10 codes to line 50 RHEUMATOID ARTHRITIS AND OTHER INFLAMMATORY POLYARTHROPATHIES) and remove from line SEVERE INFLAMMATORY SKIN DISEASE 1. L40.51 Distal interphalangeal psoriatic arthropathy 2. L40.52 Psoriatic arthritis mutilans 3. L40.53 Psoriatic spondylitis 4. L40.54 Psoriatic juvenile arthropathy 5. L40.59 Other psoriatic arthropathy d. Add line 544 to Guideline Note 21 SEVERE INFLAMMATORY SKIN DISEASE, and append “See Guideline Note 57 for the definition of mild psoriasis included on line 544.” e. Add line 430 to Guideline Note 57 MILD PSORIASIS and append “See Guideline Note 21 for the definition of moderate/severe psoriasis included on line 430.” f.